What's Up With The Jump In Viking Therapeutics Stock?

Benzinga_recent_news2025-12-05

Viking Therapeutics Inc (NASDAQ:VKTX) shares are trading higher on Thursday. The clinical-stage biopharmaceutical company seems to be benefitting from wider excitement in the obesity treatment area, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589777834?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/04/Stuttgart--Germany---01-31-2025-Person-H.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2025-12-05 03:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589777834","market":"us","top_or_hot":-1,"title":"What's Up With The Jump In Viking Therapeutics Stock?","media":"Benzinga_recent_news","content":"<div>\n<p>Viking Therapeutics Inc (NASDAQ:VKTX) shares are trading higher on Thursday. The clinical-stage biopharmaceutical company seems to be benefitting from wider excitement in the obesity treatment area, ...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/25/12/49218839/whats-up-with-the-jump-in-viking-therapeutics-stock\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What's Up With The Jump In Viking Therapeutics Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat's Up With The Jump In Viking Therapeutics Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-05 03:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/trading-ideas/movers/25/12/49218839/whats-up-with-the-jump-in-viking-therapeutics-stock><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Viking Therapeutics Inc (NASDAQ:VKTX) shares are trading higher on Thursday. The clinical-stage biopharmaceutical company seems to be benefitting from wider excitement in the obesity treatment area, ...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/25/12/49218839/whats-up-with-the-jump-in-viking-therapeutics-stock\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0198837287.USD","symbol_name":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","start_time":0,"source_url":"https://www.benzinga.com/trading-ideas/movers/25/12/49218839/whats-up-with-the-jump-in-viking-therapeutics-stock","article_id":"2589777834","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/04/Stuttgart--Germany---01-31-2025-Person-H.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/25/12/49218839/whats-up-with-the-jump-in-viking-therapeutics-stock","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2589777834","pubTimestamp":1764878220,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Viking Therapeutics Inc (NASDAQ:VKTX) shares are trading higher on Thursday. The clinical-stage biopharmaceutical company seems to be benefitting from the wider excitement in obesity treatment area and the recent positive momentum after major clinical trial developments.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0323591593.USD":"SCHRODER ISF QEP GLOBAL QUALITY \"A\" (USD) ACC","VKTX":"Viking Therapeutics, Inc.","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU1548497426.USD":"安联环球人工智能AT Acc","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU0353189763.USD":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","SGXZ99366536.SGD":"United Global Innovation A Acc SGD-H","LU1127390331.HKD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A\" (HKD) ACC","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU2360106947.USD":"BGF NUTRITION \"A4\" (USD) INC","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0234572021.USD":"高盛美国核心股票组合Acc","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU2552382215.SGD":"WELLINGTON US BRAND POWER \"A\" (SGDHDG) ACC","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","LU2471134523.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) ACC","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU2471134796.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) INC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","IE00BWXC8680.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5\" (SGD) ACC","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BK4599":"减肥药","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","LU1917777945.USD":"安联专题基金Cl AT Acc"},"translate_title":"Viking Therapeutics股票的上涨是怎么回事？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VKTX":1.5},"content_text":"Viking Therapeutics Inc (NASDAQ:VKTX) shares are trading higher on Thursday. The clinical-stage biopharmaceutical company seems to be benefitting from wider excitement in the obesity treatment area, as well as recent positive momentum after major clinical trial developments.\nWhat To Know: Viking shares have experienced volatility in recent weeks, but appear to be rebounding amid broader investor interest in GLP-1 and obesity drug developers.\nViking disclosed toward the end of November that it had completed the patient enrollment for subcutaneous VK2735 in its Phase 3 VANQUISH-1 clinical trial ahead of schedule, which was a positive surprise for investors. The firm was able to attract nearly 4,650 adults who were either obese or overweight and impacted by at least one condition associated with their weight, which was larger than the target set for the trial.\nThe rapid accrual of patients and the exceeding of the enrollment expectation were described by CEO Brian Lian as indicative of the patients’ “enthusiasm for new obesity treatments beyond those currently available.”\nThe broader obesity drug market is experiencing significant momentum, with healthcare ETFs quietly benefiting from the $150 billion obesity-drug boom. As Eli Lilly And Co (NYSE:LLY) and  Novo Nordisk A/S (NYSE:NVO) compete for dominance in the fast-growing GLP-1 market, investors are increasingly piling into diversified exposure through healthcare-focused funds. Eli Lilly shares are up about 36% over the past three months.\nEli Lilly reported adjusted earnings of $7.02 per share for the third quarter, topping expectations and prompting the company to raise its full-year outlook. Meanwhile, Novo Nordisk made a $6.5 billion counterbid for U.S. biotech Metsera, whose weight-loss research includes a longer-interval injection.\nThe intensifying competition underscores just how high the stakes are in the GLP-1 market — and it's drawing additional investor attention to emerging players like Viking Therapeutics.\nViking is currently participating in the Piper Sandler 37th Annual Healthcare Conference that wraps up on Thursday in New York City. Company executives are taking part in a fireside chat expected to inform investors on the latest developments in the clinical area.\nViking Therapeutics is currently showing strong short-term momentum, trading 6.4% above its 20-day SMA and 31.5% above its 200-day SMA. This positioning indicates a bullish trend, especially with the stock recently breaking above resistance at $39.50.\nThe RSI is currently at 49.80, which is neutral, suggesting that the stock is neither overbought nor oversold at this moment. The MACD is below the signal line so traders should watch for potential shifts if the stock approaches key support at $34.00 or resistance at $39.50.\nLooking at the three-month performance, VKTX has gained 53.61%, reflecting significant upward momentum. However, the 12-month trend tells a different story, with a decline of 23.61%, suggesting that VKTX has experienced volatility and may be recovering from a more significant downturn. This contrast between short-term gains and longer-term losses highlights the importance of monitoring the stock’s performance closely.\nCurrently, VKTX is closer to its 52-week highs than its lows. This positioning can be a double-edged sword; while it suggests strength, it also means that traders should be cautious of potential pullbacks if the stock fails to maintain upward momentum.\nVKTX Price Action: Viking Therapeutics shares were up 11.17% at $35.29 at the time of publication on Thursday, according to Benzinga Pro.\nRead Next:\nImage: Shutterstock\nThis content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589777834","isCrawlerRequest":true}